CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for gastrointestinal and metabolic disorders, today reported financial results for the quarter and year ended December 31, 2007. In addition, the Company today announced its goals and guidance for 2008, which include updates for the TrizytekTM (formerly known as ALTU-135), ALTU-238 and ALTU-237 clinical programs.
